Description: Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Home Page: guardtherapeutics.com
Nybrogatan 34, 2 tr
Stockholm,
114 39
Sweden
Phone:
46 86 70 65 51
Officers
| Name | Title |
|---|---|
| Mr. Tobias Larsson Agervald | Chief Exec. Officer |
| Ms. Karin Botha | Chief Financial Officer |
| Mr. Magnus Gram | C.S.O |
| Mr. Peter Gilmour Ph.D. | Head of Preclinical Science |
| Ms. Sara Thuresson | Head of Clinical Operations |
| Dr. Michael Reusch | Chief Medical Officer |
| Mr. Torbjorn Larsson | Head of Chemistry, Manufacturing & Controls |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9717 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |